Boston Scientific (NYSE:BSX) Upgraded at UBS Group

Boston Scientific (NYSE:BSX) was upgraded by analysts at UBS Group to a “strong-buy” rating in a research report issued on Tuesday,Zacks.com reports.

BSX has been the subject of several other reports. The Goldman Sachs Group set a $71.00 target price on shares of Boston Scientific in a research note on Thursday, May 28th. Barclays dropped their price target on Boston Scientific from $96.00 to $89.00 and set an “overweight” rating on the stock in a report on Thursday, May 28th. Weiss Ratings downgraded Boston Scientific from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Tuesday, July 7th. Canaccord Genuity Group reduced their price objective on Boston Scientific from $71.00 to $70.00 and set a “buy” rating for the company in a research note on Monday, June 1st. Finally, Evercore set a $65.00 target price on Boston Scientific in a report on Monday, July 6th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating, four have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $78.00.

Boston Scientific Price Performance

NYSE:BSX opened at $46.06 on Tuesday. The company has a quick ratio of 1.22, a current ratio of 1.90 and a debt-to-equity ratio of 0.42. The business’s 50-day moving average price is $46.57 and its 200 day moving average price is $62.73. Boston Scientific has a 52-week low of $42.20 and a 52-week high of $109.50. The firm has a market cap of $68.47 billion, a P/E ratio of 19.27, a PEG ratio of 0.88 and a beta of 0.58.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, beating analysts’ consensus estimates of $0.83 by $0.03. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The company had revenue of $5.44 billion during the quarter, compared to the consensus estimate of $5.37 billion. During the same period in the prior year, the company earned $0.75 EPS. Boston Scientific’s revenue was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, sell-side analysts predict that Boston Scientific will post 3.35 earnings per share for the current fiscal year.

Boston Scientific announced that its board has initiated a share buyback plan on Monday, May 18th that permits the company to buyback $5.00 billion in outstanding shares. This buyback authorization permits the medical equipment provider to reacquire up to 6.4% of its stock through open market purchases. Stock buyback plans are usually a sign that the company’s board of directors believes its shares are undervalued.

Insider Activity at Boston Scientific

In other news, Director Cheryl Pegus acquired 1,770 shares of the firm’s stock in a transaction that occurred on Wednesday, May 20th. The stock was purchased at an average price of $56.49 per share, with a total value of $99,987.30. Following the purchase, the director owned 1,770 shares of the company’s stock, valued at approximately $99,987.30. This trade represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Edward J. Ludwig acquired 3,580 shares of the stock in a transaction on Wednesday, May 20th. The shares were purchased at an average price of $56.68 per share, for a total transaction of $202,914.40. Following the completion of the transaction, the director owned 25,359 shares in the company, valued at approximately $1,437,348.12. This represents a 16.44% increase in their position. The SEC filing for this purchase provides additional information. In the last 90 days, insiders bought 9,800 shares of company stock worth $554,012. 0.34% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of BSX. Renaissance Group LLC purchased a new stake in shares of Boston Scientific during the fourth quarter worth $28,064,000. Rathbones Group PLC grew its stake in Boston Scientific by 20.9% in the fourth quarter. Rathbones Group PLC now owns 2,759,657 shares of the medical equipment provider’s stock valued at $263,133,000 after purchasing an additional 477,680 shares in the last quarter. Meiji Yasuda America Inc acquired a new position in Boston Scientific in the 4th quarter worth about $4,708,000. Harvest Portfolios Group Inc. increased its position in Boston Scientific by 6.1% in the 4th quarter. Harvest Portfolios Group Inc. now owns 597,341 shares of the medical equipment provider’s stock worth $56,956,000 after purchasing an additional 34,598 shares during the last quarter. Finally, LBP AM SA raised its stake in shares of Boston Scientific by 8.4% during the 4th quarter. LBP AM SA now owns 434,393 shares of the medical equipment provider’s stock worth $41,419,000 after purchasing an additional 33,534 shares in the last quarter. 89.07% of the stock is owned by institutional investors and hedge funds.

Boston Scientific News Roundup

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific reported second-quarter adjusted EPS of $0.86, above the $0.83 consensus estimate, while revenue of $5.442 billion exceeded expectations of roughly $5.36 billion. Sales increased 7.5% year over year, led by 8.3% growth in Cardiovascular and strong international performance. Boston Scientific announces results for second quarter 2026
• Positive Sentiment: The company completed a $2 billion accelerated share repurchase program and announced a $1.5 billion investment in MiRus, including an option to acquire its transcatheter aortic valve replacement business. These actions could support long-term growth and per-share results. Boston Scientific Q2 revenue rises to $5.442 billion
• Neutral Sentiment: Boston Scientific is beginning a global restructuring program expected to cost $700 million to $800 million through 2029, with anticipated headcount reductions and potential annual cost savings of about $500 million. Near-term charges may weigh on results, while savings could improve margins later. Boston Scientific expects headcount reductions amid restructuring initiative
• Negative Sentiment: The company reduced full-year 2026 adjusted EPS guidance to $3.28–$3.32 from $3.34–$3.41, below the approximately $3.36 consensus. Third-quarter EPS and revenue guidance also trail analyst expectations.
• Negative Sentiment: Management cited softer-than-expected Watchman demand, unexpected challenges in the heart-implant market and competition affecting the electrophysiology business. The lower outlook overshadowed the quarterly beat and raised concerns about growth execution. Boston Scientific trims annual profit forecast on softer Watchman device demand
• Negative Sentiment: Analysts responded by cutting price targets, including BTIG to $60 from $65, although it maintained a Buy rating. BTIG lowers Boston Scientific price target

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.